Pedro has obtained both his BSc and PhD in Biotechnology from Kings College London (University of London). He carried out research at several institutions, including the Massachusetts Institute of Technology (M.I.T.), USA and at the Technical University of Denmark (DTU). Following his Doctoral degree he specialised in medical sciences and oncology. After a Postdoctoral he undertook a 12 month Masters Degree in Management at the University of Texas, Austin, USA. He was a visiting professor at the Catholic University of Oporto, where he lectured biopharmaceutical sciences. Prior to his current position he was the Chairman & Chief Executive Officer of Biotecnol SA, in Oeiras Portugal and was a Board Member of Vida Rhein Corporation dedicated to the development Hepatitis B vaccines and other biosimilar products. Was the founder of the Portuguese Bio-industries Association and got it incorporated into EuropaBio - European Bioindustries Association. For several years he was a member of the Policy & Operations Council and Coordination Council, the Emerging Enterprises Sub-Board and the Biosimilar Products Task-Force of EuropaBio, Brussels. He has been involved in several Advisory Committees for various Portuguese Governments. He was a member of the Superior Counsel for Science, Technology and Innovation advising the Minister of Science and Technology, during the mandate of Dr. José Manuel Durão Barroso as Prime Minister of Portugal. Other recognitions included his participation in the Honour committee of the President of the of Portugal, Prof. Aníbal Cavaco Silva in 2006 and 2011. Amongst many national and international awards, Pedro has been awarded the Medal of Merit by the Oeiras Council (Portugal) in recognition for his role in promoting entrepreneurship and for services provided to the council of Oeiras.

Senior Partner and co-founder @ Quid Nunc is a family office, providing asset management services (or asset allocation only) and consolidated reporting on family's assets, trustee and corporate services. Also provides support with real estate and family governance, in various sectors. Preferred sectors are the healthcare and life sciences industries, agriculture and tourism as well sports, nutrition and life-style businesses. From January 2014 to Present (2 years) Chief Executive Officer @ Biotecnol, Ltd is a biotechnology company working in the field of immuno-oncology, owning the exclusive rights to the Tribody™ format, a proprietary technology that harbors the potential to generate the next generation of antibody based therapeutics. Biotecnol, is committed to developing the next generation of antibody-based therapeutics for the treatment of diseases in a vast number of therapeutic areas and indications based on its proprietary Tribody™ technology. The company is currently working on highly unmet needs for treating cancer subtypes. The company has programmes in Malignant mesothelioma and triple Negative Breast Cancer. There are non-disclosed activities in the development of product for treating non-solid tumours. From March 2012 to Present (3 years 10 months) Non Executive Board Member @ Move Sports Specialised in sports tours, Camps, Football, rugby, hockey, Swim, Sailing in Portugal and spain. Licensed sports travel and Tours agency. From February 2010 to Present (5 years 11 months) Chairman & Chief Executive Officer @ Biotecnol SA is a biotecnology group, providing process and product development services to the biotech and pharma industry. Biotecnol SA had its origins in Portugal and is regarded the pioneer of the biotech industry in Portugal, having been in business for over a decade. Due to its long standing activity, the company developed a wide range of internal competences along the value chain of its industry, thus allowing Biotecnol to run a sustainable business and take the opportunity to grow others. In 2009 Biotecnol SA spun-out Chrysea, a company producing insulin derivative products for use as media additives for the biopharmaceutical industry. In 2011, Biotecnol SA spun out its multispecific antibody technologies, Intellectual Property and products pipeline to its affiliate Biotecnol, Inc, a company developing the next generation of antibody-based therapeutics for the treatment of diseases in a vast number of therapeutic areas and indications based on its proprietary Tribody™ technology. From January 2000 to March 2012 (12 years 3 months) Interim General Manager @ Chrysea, is a private company part of the Biotecnol Group, producing insulin derived products for use as media additives for the biopharmaceutical industry. From 2009 to 2011 (2 years) Member of the Board of Directors @ Vida Rhein Corporation SA – a German-Portuguese joint venture, part of the Rhein Biotech NV group, dedicated to the development Hepatitis B vaccines and development of other biosimilar products. From 1998 to 2000 (2 years)

BSc, PhD, Biotechnology @ King's College London From 1988 to 1991 Metabolic Engineering and Kinetic Modeling, Chemical Engineering Department Research Fellowship with Prof. G. Stephanopoulos @ Massachusetts Institute of TechnologyMetabolic Engineering - non linear Biothermodynamics - Mathematical Modelling, DTU Research Fellowship - Department of Biotechnology with Prof Jens Nielsen @ Technical University of DenmarkManagement and Corporate Finance, Masters Degree @ The University of Texas at Austin Pedro Pissarra is skilled in: Management, Biochemistry, Biopharmaceuticals, Licensing, Intellectual Property, Team Building, Regulations, Finance, Biotechnology, Lifesciences, Mathematical Modeling, Technology Transfer, Molecular Biology, Pharmaceutical Industry, Commercialization